Analysed BRIACELL THERAPEUTICS - 30 (BCTXZ:NASDAQ) News Sources
BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models
21-04-2026
yahoo.com
BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting
20-04-2026
yahoo.com
BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License
31-03-2026
yahoo.com
BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference
18-03-2026
yahoo.com
BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License
18-02-2026
yahoo.com
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
17-02-2026
yahoo.com
BriaCell Patients’ Images Show Regression and Resolution of Metastasized Tumors and Immune Activation
28-01-2026
yahoo.com
What is the current price of BRIACELL THERAPEUTICS - 30 (BCTXZ:NASDAQ)?
The current price of BRIACELL THERAPEUTICS - 30 (BCTXZ:NASDAQ) is $0.15.
BRIACELL THERAPEUTICS - 30 (BCTXZ:NASDAQ) absolute price change since previous trading day?
The absolute price change of BRIACELL THERAPEUTICS - 30 (BCTXZ:NASDAQ) since the previous trading day is $0.001.
BRIACELL THERAPEUTICS - 30 (BCTXZ:NASDAQ) percentage price change since previous trading day?
The percentage price change of BRIACELL THERAPEUTICS - 30 (BCTXZ:NASDAQ) since the previous trading day is 0.6711%.
What is the most recent average sentiment score for BRIACELL THERAPEUTICS - 30 (BCTXZ:NASDAQ)?
The most recent average sentiment score for BRIACELL THERAPEUTICS - 30 (BCTXZ:NASDAQ) is 84 out of 100.
What is the most recent average sentiment for BRIACELL THERAPEUTICS - 30 (BCTXZ:NASDAQ)?
The most recent sentiment for BRIACELL THERAPEUTICS - 30 (BCTXZ:NASDAQ) is .
SEC-8K** Filing Available For BRIACELL THERAPEUTICS - 30 (BCTXZ:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.